BioArctic AB (publ) yakazivisa nhasi kuti US Patent uye Trademark Hofisi (USPTO) yakapa patent nyowani yemishonga yeantibody ABBV-0805, yakagadzirwa neBioArctic senzira inogona kurapa chirwere cheParkinson. Iyo patent ichaita muna Chivabvu 24, 2022, uye ichipera muna 2041, paine mukana wekuwedzera kwenguva yepentendi kusvika 2046.
The granted substance patent (US patent no. 11,339,212) inotarisa pane monoclonal antibody ABBV-0805, iyo inosunga pamwe nekubvisa pathological aggregated mafomu anonzi oligomers uye protofibrils uku ichidzivirira physiological monomer fomu yealpha-synuclein. Chinangwa ndechekugadzira mushonga unomisa kana kunonoka kufambira mberi kwechirwere cheParkinson.
PaInternational Congress yeParkinson's disease and movement disorders® (MDS) munaGunyana 2021, mibairo yakapihwa kubva muChidzidzo cheChikamu chekutanga neABBV-1 yakatsigira kuenderera mberi kwekuvandudzwa kwemasoja ekudzivirira chirwere muChikamu chechipiri nedosing kamwe chete pamwedzi.
"Tinofara kuti US Patent uye Trademark Hofisi yakapa ichi chitsva chemishonga patent yeABBV-0805, iyo inochengetedza nguva refu yekuchengetedzwa kwepatent. Sarudzo iyi inosimbisa humbowo hwetsvakiridzo yeBioArctic uye inosimbisa dziviriro yeramangwana rekurapa chirwere cheParkinson mumusika weUS, "anodaro Gunilla Osswald, CEO, BioArctic.